Cologuard® Growth Trajectory Increases to 34,000 Completed Tests, Generates $12.6M in Revenue in Third Quarter 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Exact Sciences (EXAS) Releases Light 4Q Guidance; Roth Capital Cuts Price Target to $12
October 30, 2015 8:32 AM EDTRoth Capital maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target to $12.00 (from $15.00), following the company's 3Q earnings results and guidance. Management introduced 4Q volume guidance of 42k tests. EXAS also introduced 2016 volume and revenue guidance of 240k and... More
Exact Sciences (EXAS) Misses Q3 EPS by 1c
October 29, 2015 8:25 AM EDTExact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.45), $0.01 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $12.56 million.
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
... More